Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer
type: MedicalStudy
description: A Phase II Study of Bortezomib (Velcade®, PS-341) and Docetaxel for Patients With Hormone Refractory Prostate Cancer
status: TERMINATED
study design: INTERVENTIONAL
phase: PHASE2
start date: 2005-04-30
end date: 2012-06-11
license: https://creativecommons.org/publicdomain/zero/1.0/
source: https://clinicaltrials.gov/study/NCT00183937
source organization: US National Library of Medicine
publisher: AI Analytics
sponsor: University of Southern California
study subject: Prostate Cancer
keywords: PHASE2
keywords: INTERVENTIONAL
keywords: TERMINATED
keywords: Prostate Cancer

AI Analytics
type: Organization